1M+
Over 1 million insulin pump users worldwide, each changing their infusion sets every 3 days
120M+
Insulin pump users insert over 120 million infusion sets each year
$2.7B+
Over $2.7 billion spent on insulin pump therapy
More than 1,000,000 people with diabetes on insulin pump therapy are required to change their insulin infusion catheter every two to three days. Our technology could reduce the number of infusion set changes by up to 70 million per year.
“The type 1 diabetes community will greatly benefit from next-generation devices that help maintain glucose control safely and conveniently. We believe advancing infusion set technology will improve those devices and the overall quality of life for people living with T1D.”
Aaron Kowalski, JDRF Chief Mission Officer and Vice President of Research.
Find out more
Capillary Biomedical’s SteadiSet infusion set
with SteadiFlow technology
“Our goal is to develop an infusion set that will allow people who use insulin pumps to receive more reliable insulin delivery. ”
Discover More
Research Collaboration and Funding
Capillary Biomedical thanks our leading research collaboration and funding partners.
The Sidney Kimmel Medical College of Thomas Jefferson University
Capillary Biomedical licenses intellectual property from Thomas Jefferson University and collaborates on CSII catheter development.
Pioneering Research Funding Collaborations for Artificial Pancreas Technology
Capillary Biomedical is supported with funding from JDRF, the leading global organization funding type 1 diabetes research.
Supporting Innovative Research in Diabetes Science and Technology
Capillary Biomedical has been awarded an SBIR grant from the National Institute of Diabetes and Digestive and Kidney Diseases.
Improving Lives by Supporting Health and Place-Based Initiatives in the U.S. and Globally
Capillary Biomedical has received a $1.5M program related investment in the form of a loan from the Helmsley Charitable Trust for Clinical Trials of New Insulin Infusion Technology